Adrenogenital syndrome is an umbrella category encompassing abnormal sex differentiation and congenital disorders of sex development arising from abnormal levels of steroid hormones produced by the gonads or adrenal glands. The underlying pathophysiology involves defects in steroid biosynthesis pathways, including those found in congenital adrenal hyperplasia and adrenal cortex neoplasms. The condition group is genetically and clinically heterogeneous; no specific causal genes are enumerated in this packet's known_genes field for the umbrella entity. Individual subtypes within this category have distinct etiologies, biochemical profiles, and clinical trajectories.

Clinical features of adrenogenital syndrome are defined by the pattern of abnormal steroid biosynthesis and the degree to which androgenic or estrogenic hormones are over- or under-produced relative to the biological sex of the affected individual. The definition documented in this packet identifies virilization in females, feminization in males, and precocious sexual development in children as characteristic presentations. Specific phenotypic frequencies are not enumerated for this umbrella entity in this packet, as they depend on the particular subtype involved.

The adrenogenital syndrome category encompasses disorders caused by enzymatic defects in adrenal steroid biosynthesis, leading to excess production of androgens or other steroids and insufficient production of glucocorticoids or mineralocorticoids depending on the specific enzyme affected. In congenital adrenal hyperplasia, the most recognized subgroup, defects in enzymes such as 21-hydroxylase are the predominant cause. Because the condition is described as an umbrella entity in this packet, causal genes are not listed in the known_genes field, and inheritance patterns are not specified. Individual subtypes have their own distinct genetic etiologies.

Diagnosis within the adrenogenital syndrome category is guided by clinical presentation, hormonal biochemistry (including measurement of serum cortisol, adrenal androgens, and mineralocorticoid levels), and imaging of the adrenal glands. For subtypes with recognized genetic etiologies, molecular genetic testing supports confirmatory diagnosis. Newborn screening programs in many jurisdictions include testing for congenital adrenal hyperplasia, the most prevalent subtype within this umbrella category. Specific diagnostic criteria for the umbrella entity are not enumerated in this packet.

No FDA-approved pharmacological treatments are listed in this packet for adrenogenital syndrome as an umbrella entity. Management approaches in the published literature for individual subtypes—particularly congenital adrenal hyperplasia—have centered on glucocorticoid replacement to suppress excess adrenal androgen production and, when applicable, mineralocorticoid replacement. No orphan drug designations are listed in this packet for the umbrella entity. Investigational pharmacological approaches are under evaluation in active clinical trials specific to CAH subtypes.

The prognosis of conditions within the adrenogenital syndrome category depends on the specific subtype, the degree of hormonal imbalance, and the timing and effectiveness of intervention. For subtypes identifiable at birth through newborn screening, early intervention can significantly alter the clinical course. Longer-term outcomes vary by subtype and are not enumerated for the umbrella entity in this packet.

Research activity associated with adrenogenital syndrome-related conditions is extensive. This packet's research digest documents 246 classified publications, with reviews and meta-analyses as the dominant type, alongside biomarker and recent trial publications. Active clinical trials listed in this packet are specific to congenital adrenal hyperplasia (CAH) rather than the umbrella entity: these include a Phase 2 study of a treatment in pediatric CAH participants (Balance-CAH, NCT07159841, Crinetics Pharmaceuticals) and a Phase 3 study evaluating atumelnant in adult CAH patients (NCT07144163, Crinetics Pharmaceuticals). Drug therapy and biologic therapy are among the active intervention categories; no gene therapy trials are listed. Sponsor profiles include pharmaceutical companies Adrenas Therapeutics and Crinetics Pharmaceuticals, as well as H. Lundbeck A/S.